Estimation of Utility Weights for Prostate-related Health States in Korea |
Kim, Seon-Ha
(Department of Nursing, Dankook University)
Ock, Minsu (Department of Preventive Medicine, Ulsan University Hospital, University of Ulsan College of Medicine) Jo, Min-Woo (Department of Preventive Medicine, University of Ulsan College of Medicine) Park, Sungchan (Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine) |
1 | Kim Y, Hwang JS, Ahn J, Lee SM, Lee YJ, Shin S. Utilities for prostate cancer by cancer stage and treatment step in Korea. Korean J Health Econ Policy 2013;19(2):1-20 (Korean). |
2 | Jo MW, Kwon DS, Kim SH, Kil SR, Lee SI. Validity and reliability of Korean EQ-5D valuation study using a computer-assisted standard gamble method. Korean J Health Promot 2010;10(3):105-112 (Korean). |
3 | Torvinen S, Farkkila N, Sintonen H, Saarto T, Roine RP, Taari K. Health-related quality of life in prostate cancer. Acta Oncol 2013;52(6):1094-1101. DOI |
4 | Kim SH, Jo MW, Ock M, Lee HJ, Lee JW. Estimation of health state utilities in breast cancer. Patient Prefer Adherence 2017;11:531-536. DOI |
5 | Bergius S, Torvinen S, Muhonen T, Roine RP, Sintonen H, Taari K. Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment. Scand J Urol 2017;51(1):13-19. DOI |
6 | Smith KJ, Roberts MS. Quality-of-life utility values for erectile function and sildenafil treatment. Clin Drug Investig 2005;25(2):99-105. DOI |
7 | Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 2002;12(2):160-178. DOI |
8 | Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions; 2010 [cited 2021 Jul 1]. Available from: https://www.york.ac.uk/media/che/documents/papers/researchpapers/rp54_appropriate_perspectives_for_health_care_decisions.pdf. |
9 | Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003;41(1):153-164. DOI |
10 | Gries KS, Regier DA, Ramsey SD, Patrick DL. Utility estimates of disease-specific health states in prostate cancer from three different perspectives. Appl Health Econ Health Policy 2017;15(3):375-384. DOI |
11 | Krahn MD, Bremner KE, Tomlinson G, Naglie G. Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapy. Prostate Cancer Prostatic Dis 2009;12(4):361-368. DOI |
12 | Postulart D, Adang EM. Response shift and adaptation in chronically ill patients. Med Decis Making 2000;20(2):186-193. DOI |
13 | Wittenberg E, Halpern E, Divi N, Prosser LA, Araki SS, Weeks JC. The effect of age, race and gender on preference scores for hypothetical health states. Qual Life Res 2006;15(4):645-653. DOI |
14 | Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 2007;45(3):259-263. DOI |
15 | Roehrborn CG, Egan KB, Miner MM, Ni X, Wong DG, Rosen RC. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment. BJU Int 2016;118(1):153-160. DOI |
16 | Kim SH, Lee SI, Jo MW. Feasibility, comparability, and reliability of the standard gamble compared with the rating scale and time trade-off techniques in Korean population. Qual Life Res 2017;26(12):3387-3397. DOI |
17 | Morant S, Bloomfield G, Vats V, Chapple C. Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. J Sex Med 2009;6(4):1103-1110. DOI |
18 | Park HJ, Won JE, Sorsaburu S, Rivera PD, Lee SW. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World J Mens Health 2013;31(3):193-207. DOI |
19 | Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA, et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology 2009;73(3):562-566. DOI |
20 | Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005, p. 147-173. |
21 | Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 2001;21(4):329-334. DOI |
22 | Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst 2017;109(9):djx030. |
23 | Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249. DOI |
24 | Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61(6):1079-1092. DOI |
25 | Wee HL, Li SC, Xie F, Zhang XH, Luo N, Feeny D, et al. Validity, feasibility and acceptability of time trade-off and standard gamble assessments in health valuation studies: a study in a multiethnic Asian population in Singapore. Value Health 2008;11 Suppl 1:S3-S10. DOI |
26 | Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5(1):1-30. DOI |
27 | Norman R, Cronin P, Viney R, King M, Street D, Ratcliffe J. International comparisons in valuing EQ-5D health states: a review and analysis. Value Health 2009;12(8):1194-1200. DOI |
28 | Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010;96:5-21. DOI |
29 | Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al, Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 2018;124(13):2785-2800. DOI |
30 | Won YJ, Jung KW, Oh CM, Park EH, Kong HJ, Lee DH, et al. Geographical variations and trends in major cancer incidences throughout Korea during 1999-2013. Cancer Res Treat 2018;50(4):1281-1293. DOI |
31 | Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol 2018;25(6):524-531. DOI |
32 | Lee KS, Chang HS, Lee SM, Park EC. Economic burden of cancer in Korea during 2000-2010. Cancer Res Treat 2015;47(3):387-398. DOI |
33 | Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. J Health Econ 1996;15(2):209-231. DOI |
34 | Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Econ 1997;16(2):155-175. DOI |
35 | Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 2018;50(2):303-316. DOI |
36 | Lee YJ, Lee JW, Park J, Seo SI, Chung JI, Yoo TK, et al. Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea. Investig Clin Urol 2016;57(6):424-430. DOI |
37 | Robert G, De La Taille A, Descazeaud A. Epidemiology of benign prostatic hyperplasia. Prog Urol 2018;28(15):803-812 (French). DOI |
38 | Glina S, Santana AW, Azank F, Mello LF, Moreira ED Jr. Lower urinary tract symptoms and erectile dysfunction are highly prevalent in ageing men. BJU Int 2006;97(4):763-765. DOI |
39 | Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci 1976;10(3):129-136. DOI |
40 | Bremner KE, Chong CA, Tomlinson G, Alibhai SM, Krahn MD. A review and meta-analysis of prostate cancer utilities. Med Decis Making 2007;27(3):288-298. DOI |